TY - JOUR
T1 - Targeted α particle immunotherapy for myeloid leukemia
AU - Jurcic, Joseph G.
AU - Larson, Steven M.
AU - Sgouros, George
AU - McDevitt, Michael R.
AU - Finn, Ronald D.
AU - Divgi, Chaitanya R.
AU - Ballangrud, Åse M.
AU - Hamacher, Klaus A.
AU - Ma, Dangshe
AU - Humm, John L.
AU - Brechbiel, Martin W.
AU - Molinet, Roger
AU - Scheinberg, David A.
PY - 2002/8/15
Y1 - 2002/8/15
N2 - Unlike β particle-emitting isotopes, a emitters can selectively kill individual cancer cells with a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically targets myeloid leukemia cells and has activity against minimal disease. When labeled with the β-emitters 131I and 90Y, HuM195 can eliminate large leukemic burdens in patients, but it produces prolonged myelosuppression requiring hematopoietic stem cell transplantation at high doses. To enhance the potency of native HuM195 yet avoid the nonspecific cytotoxicity of β-emitting constructs, the α-emitting isotope 213Bi was conjugated to HuM195. Eighteen patients with relapsed and refractory acute myelogenous leukemia or chronic myelomonocytic leukemia were treated with 10.36 to 37.0 MBq/kg 213Bi-HuM195. No significant extramedullary toxicity was seen. All 17 evaluable patients developed myelosuppression, with a median time to recovery of 22 days. Nearly all the 213Bi-HuM195 rapidly localized to and was retained in areas of leukemic involvement, including the bone marrow, liver, and spleen. Absorbed dose ratios between these sites and the whole body were 1000-fold greater than those seen with β-emitting constructs in this antigen system and patient population. Fourteen (93%) of 15 evaluable patients had reductions in circulating blasts, and 14 (78%) of 18 patients had reductions in the percentage of bone marrow blasts. This study demonstrates the safety, feasibility, and antileukemic effects of 213Bi-HuM195, and it is the first proof-of-concept for systemic targeted a particle immunotherapy in humans.
AB - Unlike β particle-emitting isotopes, a emitters can selectively kill individual cancer cells with a single atomic decay. HuM195, a humanized anti-CD33 monoclonal antibody, specifically targets myeloid leukemia cells and has activity against minimal disease. When labeled with the β-emitters 131I and 90Y, HuM195 can eliminate large leukemic burdens in patients, but it produces prolonged myelosuppression requiring hematopoietic stem cell transplantation at high doses. To enhance the potency of native HuM195 yet avoid the nonspecific cytotoxicity of β-emitting constructs, the α-emitting isotope 213Bi was conjugated to HuM195. Eighteen patients with relapsed and refractory acute myelogenous leukemia or chronic myelomonocytic leukemia were treated with 10.36 to 37.0 MBq/kg 213Bi-HuM195. No significant extramedullary toxicity was seen. All 17 evaluable patients developed myelosuppression, with a median time to recovery of 22 days. Nearly all the 213Bi-HuM195 rapidly localized to and was retained in areas of leukemic involvement, including the bone marrow, liver, and spleen. Absorbed dose ratios between these sites and the whole body were 1000-fold greater than those seen with β-emitting constructs in this antigen system and patient population. Fourteen (93%) of 15 evaluable patients had reductions in circulating blasts, and 14 (78%) of 18 patients had reductions in the percentage of bone marrow blasts. This study demonstrates the safety, feasibility, and antileukemic effects of 213Bi-HuM195, and it is the first proof-of-concept for systemic targeted a particle immunotherapy in humans.
UR - http://www.scopus.com/inward/record.url?scp=0037103293&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0037103293&partnerID=8YFLogxK
U2 - 10.1182/blood.v100.4.1233.h81602001233_1233_1239
DO - 10.1182/blood.v100.4.1233.h81602001233_1233_1239
M3 - Article
C2 - 12149203
AN - SCOPUS:0037103293
SN - 0006-4971
VL - 100
SP - 1233
EP - 1239
JO - Blood
JF - Blood
IS - 4
ER -